Today: 7 February 2026
Subscribe
Browse Category

NYSE:CMA News 10 December 2025 - 5 February 2026

Comerica stock price: CMA stops trading after Fifth Third merger — what shareholders own now

Comerica stock price: CMA stops trading after Fifth Third merger — what shareholders own now

Comerica shares stopped trading after Fifth Third Bancorp closed its acquisition and delisted CMA from the NYSE. Each Comerica share was converted into 1.8663 Fifth Third shares, valuing them at about $100.39 based on current prices. Fitch withdrew Comerica’s credit ratings after the deal. Fifth Third plans to finish systems integration by Labor Day, with Comerica branches keeping their name until then.
5 February 2026
··
Comerica stock stops trading after Fifth Third merger closes — what shareholders need to know now

Comerica stock stops trading after Fifth Third merger closes — what shareholders need to know now

Comerica shares have been suspended and will be delisted from the NYSE after its merger with Fifth Third Bancorp closed Feb. 1, according to SEC filings. Each Comerica share converts to 1.8663 Fifth Third shares. Comerica last traded near $88.67 on Jan. 30. Fifth Third, now the ninth-largest U.S. bank, will deregister Comerica’s securities and halt its SEC reporting.
3 February 2026
··
Fifth Third stock ticks up premarket after Comerica merger closes — what FITB investors watch next

Fifth Third stock ticks up premarket after Comerica merger closes — what FITB investors watch next

Fifth Third Bancorp shares rose 0.8% premarket Monday after it completed its $10.9 billion all-stock acquisition of Comerica, creating the ninth-largest U.S. bank with $294 billion in assets. Comerica shares will be delisted, and three former Comerica directors join Fifth Third’s board. The company expects full system and brand conversions in the third quarter. Investors await combined financials and integration updates.
2 February 2026
··
Fifth Third–Brex Deal Puts $5.6B AI-Powered Card Platform at Center of Comerica Merger Fight

Fifth Third–Brex Deal Puts $5.6B AI-Powered Card Platform at Center of Comerica Merger Fight

As Fifth Third Bank chooses Brex to power its commercial cards, the regional lender faces activist lawsuits and community protests over its planned Comerica acquisition. CINCINNATI / DALLAS / NEW YORK — December 10, 2025 Key Points Fifth Third turns to Brex for AI‑powered commercial cards On December 9, Fifth Third Bank announced a multi‑year partnership with Brex, under which the fintech will power the bank’s commercial card program across its commercial banking franchise. Fifth Third Bank+2Business Wire+2 According to the joint announcement, the deal: Fifth Third CEO and chair Tim Spence framed the move as a strategic bet on
10 December 2025
····

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop